Auryon Atherectomy System

What Auryon Atherectomy System does

Auryon Atherectomy System is a peripheral atherectomy medical device platform used to treat peripheral artery disease (PAD) in infrainguinal arteries above and below the knee, including in-stent restenosis (ISR). The system originated as Eximo Medical's B-Laser technology and was acquired by AngioDynamics, Inc. (NASDAQ: ANGO), under which it now operates as a branded product line. At its core, the platform is a Class IIb medical device containing a Class IV solid-state laser that emits 355nm UV pulses at 10-25 nanosecond widths, a combination engineered to selectively vaporize lesion tissue and calcium while preserving the vessel wall endothelium. The system consists of a portable laser console (110V, touch-screen, ~198 lb, small footprint) and five single-use catheter sizes (0.9mm through 2.35mm) covering reference vessel diameters from approximately 1.4mm to 3.0mm and anatomies from above the knee to below the ankle, with the 2.0mm and 2.35mm catheters adding built-in aspiration to reduce distal embolization risk.

The business model is a classic medtech razor-and-blade construct. The Auryon laser console is sold as capital equipment to healthcare facilities under multi-year contracts (list part number EXM-2001-1100), and recurring revenue comes from single-use catheter SKUs (EXM-4001 through EXM-4012) priced per unit with standard and hydrophilic-coated variants. The go-to-market is enterprise direct sales through AngioDynamics' field representatives targeting hospital catheterization labs, interventional cardiology and vascular surgery departments, and the rapidly growing office-based lab (OBL) and ambulatory surgery center (ASC) channel. The system holds FDA 510(k) clearance and CE Mark for atherectomy of arterial stenoses including ISR (on the larger two catheters) and thrombus aspiration, supported by the EX-PAD-03 pivotal IDE trial (NCT03157531) conducted across 8 US and 3 EU sites in 97 patients/107 lesions. Marketing is digital-first and evidence-led, built around peer-reviewed clinical publications, case studies, physician-perspective video content, and conference participation.

Customer concentration is best characterized as Moderate with limited disclosure: only two institutional case-study customers are named (Midwest Cardiovascular Research Foundation and Heart & Vascular Institute of Texas), while the underlying end market is fragmented across hospitals and OBLs/ASCs in the US and EU. Pricing is non-public and negotiated through AngioDynamics representatives. The platform is currently in active commercial scaling rather than hyper-growth, evidenced by ongoing catheter portfolio updates (2025 imagery), continued clinical-evidence publication, and explicit OBL/ASC channel expansion. Key forward-looking risks include competitive pressure from incumbent peripheral atherectomy franchises (Boston Scientific, Medtronic, Philips), reimbursement variability for PAD interventions in OBL settings, and the long-term strategic priority AngioDynamics assigns to Auryon relative to its broader portfolio.

Name

Auryon Atherectomy System

Legal name

AngioDynamics, Inc.

Website

https://auryon-system.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Auryon Atherectomy System is a Class IV laser-based peripheral atherectomy platform owned by AngioDynamics that uses 355nm wavelength technology to treat infrainguinal PAD, including ISR, in hospitals and office-based labs.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Intervention Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

• Peripheral atherectomy devices
• Laser atherectomy systems
• Vascular intervention devices
• Peripheral artery disease treatment
• Atherectomy catheters

Headquarters

HQ city

Latham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Auryon Laser System (Capital Equipment): The Auryon Laser System is sold as capital equipment to hospitals and office-based labs. The system includes the laser console with touch screen interface, foot pedal for hands-free activation, and accessories. Pricing is not publicly disclosed and likely involves direct sales negotiation.
2. Atherectomy Catheters (Consumables): Single-use atherectomy catheters in multiple sizes (0.9mm to 2.35mm) are sold as consumable disposables. Available in standard and hydrophilic-coated (H000) variants. XL longer-length catheters (225cm) are also available for specific anatomies. Part numbers include EXM-4002 through EXM-4012 series.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

The Auryon Atherectomy System is a Class IV laser-based peripheral atherectomy platform that uses a 355nm wavelength laser with nanosecond pulse width (10-25 ns) to selectively ablate atherosclerotic lesions in infrainguinal arteries while preserving the vessel endothelium. The system consists of a portable laser console and a portfolio of five single-use catheter sizes (0.9mm to 2.35mm) that treat all lesion types — including in-stent restenosis (ISR), calcified lesions, and chronic total occlusions — both above and below the knee.

Product overview

The Auryon Atherectomy System is a peripheral atherectomy platform consisting of a portable laser console unit and five distinct catheter sizes (0.9mm, 1.5mm, 1.7mm, 2.0mm, and 2.35mm) designed to treat all infrainguinal arterial lesions above and below the knee. The system uses 355-nm wavelength laser technology with 10-25 ns pulse width to selectively ablate lesion tissue while preserving vessel endothelium. The catheters range from 4 Fr to 7 Fr and are designed for different vessel sizes and treatment locations, with the larger 2.0mm and 2.35mm catheters featuring built-in aspiration capability. The platform is indicated for arterial stenoses including in-stent restenosis (ISR) and thrombus aspiration in native and stented infrainguinal arteries.

Differentiator

Problem solved

Functional benefit

Products and services

• Auryon Atherectomy System A peripheral atherectomy platform for treating peripheral artery disease (PAD) using 355-nm wavelength laser technology to selectively ablate lesion tissue while preserving vessel wall endothelium. Indicated for atherectomy of arterial stenoses including in-stent restenosis (ISR) and thrombus aspiration in native and stented infrainguinal arteries. Sold to hospitals, cath labs, and office-based labs (OBLs).
• Auryon Laser Console (EXM-2001-1100) The main laser console unit of the Auryon System (part number EXM-2001-1100 for 100-120 VAC). Designed for portability with 110V wall outlet operation, touch-screen interface, LED activity indicator, solid-state laser design (no gas, no calibration), foot pedal for hands-free activation, and low acoustic noise. Weighs 198.45 lb with dimensions 29 in (L) x 37 in (H) x 13.3 in (W). Sold as capital equipment to hospitals and OBLs.
• Auryon Atherectomy Catheters (0.9mm, 1.5mm, 1.7mm, 2.0mm, 2.35mm) Single-use atherectomy catheters available in five sizes (0.9mm, 1.5mm, 1.7mm, 2.0mm, 2.35mm) with 4-7 Fr diameters and working lengths from 110-225 cm (XL), to treat all infrainguinal arteries from above the knee to below the ankle. The 2.0mm and 2.35mm catheters include built-in aspiration to reduce distal embolization risk, and the 2.35mm features a built-in off-centering mechanism for eccentric lesions. Hydrophilic-coated variants (H000 suffix) are available. Sold as consumable disposables using part numbers EXM-4001 through EXM-4012.

Quantifiable outcome

• 31-38% reduction in stenosis prior to any adjunctive therapy regardless of calcification level, lesion type, lesion length, or catheter used
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Medtronic: Acquired Covidien's peripheral vascular portfolio including the HawkOne directional atherectomy system and the TurboElite laser atherectomy line. A direct competitor in hospital-based peripheral atherectomy with a much larger global sales force and broader clinical evidence base.
• Boston Scientific: Markets the Jetstream atherectomy system (acquired from Pathway Medical) for peripheral artery disease treatment. Competes with Auryon in both hospital and OBL channels for infrainguinal lesion preparation.
• Philips (Spectranetics): Philips acquired Spectranetics, the established leader in laser atherectomy (Turbo-Elite, Turbo-Tandem) for peripheral and coronary indications. Directly competes with Auryon in peripheral laser atherectomy with overlapping indications and similar Class IV laser technology.
• Penumbra: Penumbra's Indigo thrombectomy/atherectomy system is used in peripheral vascular interventions including PAD. Competes in vessel preparation and aspiration-based peripheral procedures, overlapping with Auryon's built-in aspiration capability.
• Abbott (Cardiovascular Systems / CSI): Abbott acquired Cardiovascular Systems Inc. (CSI), maker of the Diamondback 360° orbital atherectomy system, one of the most widely used peripheral atherectomy platforms. Competes head-to-head with Auryon in calcified lesion treatment and OBL/ASC settings.

Emerging players

• Shockwave Medical: Markets intravascular lithotripsy (IVL) for calcium modification in peripheral and coronary arteries. While not a direct atherectomy competitor, IVL is increasingly used as an alternative vessel-preparation strategy and competes for the same PAD procedure share.
• Walk Vascular: Walk Vascular markets peripheral thrombectomy and aspiration systems (e.g., JETi) used in PAD and venous interventions. A smaller emerging player with partial overlap to Auryon's aspiration-enabled catheter portfolio.
• Ra Medical Systems: Markets the DABRA laser atherectomy system, another laser-based peripheral atherectomy platform. Smaller and less commercially mature than Auryon but uses similar laser ablation technology and competes in similar procedure types.

Broad incumbents

• BD (Bard Peripheral Vascular): BD's peripheral vascular portfolio includes atherectomy, thrombectomy, and vessel-preparation products serving the same hospital and OBL customers as Auryon, though it competes more broadly across multiple vascular device categories.
• AngioDynamics (Parent): AngioDynamics (NASDAQ: ANGO) is the parent company of the Auryon System and operates adjacent peripheral vascular, venous, and oncology franchises. Comparable as the corporate parent and a broader incumbent in the peripheral intervention space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AuryonPad
• Facebookbusiness.facebook.com/angiodynamics
• LinkedInlinkedin.com/company/auryon-atherectomy-system

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auryon Atherectomy System